Briacell Therapeutics Corp T.BCT

Alternate Symbol(s): BCTX | BCTXW

Healthcare Biotechnology

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The Company is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. It is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.

TSX:BCT - Post by User

Briacell Therapeutics Corp

Bullboard Posts

Post by Sh99999on Oct 19, 2018 6:03am

48 Views

Post# 28832744

for information Medicenna other clinical stage immunotherapy

C:MDNA for information Medicenna other clinical stage immunotherapy company similar Briacell

today + 25% around 60 m cap

Medicenna Amends Protocol of Phase 2b Glioblastoma Study of

MDNA55 has completed three clinical trials in 72 patients, including 66 adults with rGBM
Briacell;(we are really anonymous who we lose our sp progress)

Bullboard Posts

AI companies to invest in